𝙎𝙝𝙖𝙞𝙠𝙝𝙖𝙝 | شيخة

كُل أمنياتي .. أنّي إلـيّ تُعيدني أحلامي☄️

[عبدالرّحمٰن @a6dulrahmann]

الرحلة لا تُقاس بما غَنِمَتْهُ يداك، بل بما صنعته في نفسك.

[Dr Rishabh Jain @DrRishabhOnco]

#ASCO26

ER+, HER2- breast cancer management is becoming less about “one-size-fits-all” and more about precision escalation vs precision de-escalation.

The future is clear:
🧬 Biomarkers decide who gets chemo
💊 CDK4/6 inhibitors move earlier
🩺 Endocrine therapy intensifies in high-risk disease
⚖️ Obesity and supportive care become survival interventions

Key themes from ASCO 2026:
▪️ Anthracyclines may still matter in selected genomically high-risk patients
▪️ Some node+ patients may safely avoid chemotherapy
▪️ OFS + AI remains critical for high-risk premenopausal disease
▪️ Adjuvant abemaciclib and ribociclib continue reshaping standards
▪️ Oral SERDs are entering early breast cancer
▪️ Weight management may become part of oncologic care itself

Breast oncology is shifting from anatomy-driven to biology-driven treatment selection.

Which biomarker do you think will have the biggest impact in early ER+ breast cancer over the next 5 years? 👀

@OncoAlert @ASCO @myesmo @esmo_open @larvol

#OncoTwitter #MedTwitter #BreastCancer #bcsm #PrecisionOncology

[Yakup Ergün @dr_yakupergun]

#ASCO26

First-Line Therapy: Choosing the Endocrine Backbone for CDK4/6i

Alexandru E. Eniu, MD

[Yakup Ergün @dr_yakupergun]

Current approved treatment options for HR+, HER2− mBC

ESMO Guidelines: Real World Cases Webinar: Metastatic Breast Cancer 2026 presentation

https://t.co/H3S9DZXsK2

[Veli Bakalov, MD @HemeOncBuddy]

Launching https://t.co/XPqbIcgSFT today = 5 years of hard work!

A free, oncologist-curated heme/onc resource — built for the bedside, the boards, and everyone in between.

Every entry cross-checked against OpenEvidence
@EvidenceOpen = Zero errors flagged.

What's inside ↓

[MV Chandrakanth @ChandrakanthMv]

ESMO Breast 2026 — key trials at a glance

• HER2+ trials
• HR+/HER2− trials
• TNBC / ADC / Immunotherapy trials

Major studies, key results, and clinical take-home messages — all in one quick visual summary.

#ESMOBreast2026 #BreastCancer #Oncology #MVOnco

[Cristiano Ronaldo @Cristiano]

Your support has pushed us every single week. In the stadium, at home and everywhere around the world. That energy is with us on the pitch.

Let’s make it count. For us. For you. For Nassr.
See you tomorrow. 💥

[𝙎𝙝𝙖𝙞𝙠𝙝𝙖𝙝 | شيخة @shaikhah155]

ما من شيء بوسعه أن يحجب الشمس عن روحك ، فالضوء نافذ والنور وارد والصبح دائماً قريب 🩶

[أمـــل السهلاوي 🇦🇪 @SahLawiA]

حتى نولد من جديد ♥️

[Entisar saleh @Entisar_kilani]

Oral SERDs in practice .

#oncology #medtwitter #breastcancer

[MV Chandrakanth @ChandrakanthMv]

HER2+ early breast cancer — can we omit chemotherapy?
PHERGain (5-year results):
• PET-guided strategy
• ~1/3 patients avoided chemotherapy
• Excellent outcomes in responders
Key takeaway:
👉 Response-adapted de-escalation is feasible in selected patients
⚠️ Phase II data
#BreastCancer #HER2 #Oncology #ESMOBreast2026 #MVOnco

[𝙎𝙝𝙖𝙞𝙠𝙝𝙖𝙝 | شيخة @shaikhah155]

يسألوني- فؤاد عبدالواحد 💗💗🥹

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🎭 What defines a good oncologist?
🧩 7 key pillars:
💛 Patient-centered care
🤝 Relationships
🗣️ Authentic communication
🧠 Emotional intelligence
⚖️ Coping with burden
🌍 Embracing uncertainty
📚 Lifelong learning

✨ Beyond skills → humanistic oncology

🔗 https://t.co/LjI9XNWjP6
@OncoAlert

[Yakup Ergün @dr_yakupergun]

Algorithm for Systemic Therapy in HER2-Positive Breast Cancer

(Based on NCCN and ESMO guidelines; recommendations in gray areas reflect the St. Gallen 2025 consensus and, in part, my own clinical judgment)

[Dr. Nina Niu Sanford @NiuSanford]

Here is Version 2.0 of when to hold systemic tx during RT. Updated & w 3 additional drug categories (ADCs, CDK4/6 inhibitors, PARPi).

More details on newer drugs in 🧵 below.

Please use this version as reference & thanks for all input/experience crowdsourcing! (1/3)

[ِ @ShrougDu3aa]

https://t.co/6DMQ79Coz2

[𝙎𝙝𝙖𝙞𝙠𝙝𝙖𝙝 | شيخة @shaikhah155]

أجر لك وأجر لي
ساهم معي في التبرع لـ (صدقة جارية عن عبدالرحمن بن ماطر الحربي رحمه الله) عبر #منصة_إحسان: https://t.co/jk3qbAgLvH #

[𝙎𝙝𝙖𝙞𝙠𝙝𝙖𝙝 | شيخة @shaikhah155]

أجر لك وأجر لي
ساهم معي في التبرع لـ (صدقة جارية عن عبدالله العمر رحمه الله) عبر #منصة_إحسان: https://t.co/HrI2ENlT1A

[𝙎𝙝𝙖𝙞𝙠𝙝𝙖𝙝 | شيخة @shaikhah155]

July 2025 🧡🌅